Inclusion Criteria:  The women aged <40 years old. Rare menstruation or menopause for at least 4 months. Serum basal follicle stimulating hormone (FSH) level ≥15 IU/L at least twice inspection (two occasions >4 weeks apart). Rare menstruation or menopause for at least 4 months. Individuals meeting the above criteria who voluntarily consented to study participation.  Exclusion Criteria:  Pregnant and lactating patients; Patients with endometriosis, adenomyosis, endometrial lesions (submucous fibroids, endometrial polyps, etc.), hysteromyoma > 4cm or hysterectomy; Patients with known or suspected breast cancer history and estrogen-dependent malignant tumor; Patients with personal history of venous thromboembolism (VTE) or high risk of VTE (including body mass index > 30 kg/m2, smoking and family history of thrombosis); Patients with porphyria; Patients with serious primary diseases or mental illness such as cardiovascular, liver, kidney and hematopoietic system; Patients who are participating in other clinical trials or have participated in other clinical trials in the past three months; Patients who suspect or have a history of alcohol and drug abuse; Patients who are known to be allergic to the test drugs or their components; The researchers determined that patients are not suitable for this trial.